Cargando…
Review on molnupiravir as a promising oral drug for the treatment of COVID-19
During the COVID-19 pandemic, various drug candidates have been developed, molnupiravir (MK-4482 and EIDD-2801), which is a new orally anti-viral agent under development for the treatment of COVID-19, is under study in the final stage of the clinical trial. Molnupiravir enhances the replication of v...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer US
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8721938/ https://www.ncbi.nlm.nih.gov/pubmed/35002192 http://dx.doi.org/10.1007/s00044-021-02841-3 |